ARTICLE | Company News
Halaven sales and marketing update
November 7, 2016 11:14 PM UTC
The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Halaven eribulin mesylate to treat advanced or metastatic breast cancer in patients who have received ≥2 prior chem...
BCIQ Company Profiles